Physicians, researchers, regulators, pharmaceutical industry leaders, and patient advocates came together recently at the U.S. Food & Drug Administration (FDA) to work towards getting treatments approved more quickly for pediatric lupus. CARRA and the Pediatric Rheumatology Collaborative Study Group (PRCSG) collaborated to plan the FDA Workshop: Accelerating Product Development for Pediatric Systemic Lupus Erythematosus (SLE). This important …